Premium
Characteristics and progression‐free survival of Afro‐Caribbean men with metastatic hormone‐sensitive prostate cancer at the time of diagnosis
Author(s) -
Rossignol Thibault,
Gourtaud Gilles,
Senechal Cédric,
Sadreux Yvane,
Roux Virginie,
Blanchet Pascal,
Brureau Laurent
Publication year - 2021
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.24206
Subject(s) - medicine , prostate cancer , oncology , androgen deprivation therapy , population , progression free survival , proportional hazards model , clinical endpoint , univariate analysis , prostate specific antigen , cancer , hazard ratio , gynecology , chemotherapy , multivariate analysis , randomized controlled trial , confidence interval , environmental health
and Objectives Metastatic hormone‐sensitive prostate cancer (mHSPC) accounts for 12% of prostate cancers diagnosed in Guadeloupe according to the Guadeloupean cancer registry. Most published studies have been conducted on the Caucasian population, whereas data concerning mHSPC in the Afro‐Caribbean population are lacking. We aimed to describe the patient characteristics and estimate the progression‐free survival of men with mHSPC in an Afro‐Caribbean population according to the available treatment. Patients and Methods This was a monocentric retrospective study that consecutively included 133 men with mHSPC between January 1, 2015 and December 31, 2019 at the University Hospital of Guadeloupe. The primary endpoint was a description of the patients' characteristics with a description of complications at diagnosis. The secondary endpoint was progression‐free survival. Kaplan–Meier survival and Cox proportional hazard analyses were performed. Results The median age at diagnosis was 71 years. The median prostate‐specific antigen (PSA) was 147 ng/ml and 37% of patients presented with a disease‐related complication at diagnosis. The survival analysis according to treatment showed median survival of 15 months for the androgen deprivation therapy (ADT) + chemotherapy group, 20 months for the ADT + new hormone therapy group, and 21.5 months for the ADT alone group, with no significant difference between the three therapeutic options (log‐rank test: 0.27). In univariate analysis, none of the patient characteristics at diagnosis (i.e., age, PSA, bone lesions, visceral lesions) were significantly associated with the risk of progression, regardless of the treatment. Conclusion There was no significant difference in terms of progression‐free survival between currently validated treatments administered in the first line, regardless of the tumor volume or risk group. Future studies with larger numbers of patients and involving molecular factors are required to confirm or invalidate these results and understand the evolution of prostate cancer in our population and thus better prevent complications related to the disease.